ログイン

SUMMATIVE PART 2

SUMMATIVE PART 2
50問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    The percentage of red cells recovered after thawing and deglycerolization of frozen blood is: A. 35% B. 50% C. 70% D. 80%

    D. 80%

  • 2

    Frozen and thawed RBCs processed in an open system can be stored for how many days/hours? A. 3 days B. 6 hours C. 24 hours D. 15 days

    C. 24 hours

  • 3

    For apheresis donors who donate platelets, a platelet count must be performed prior to the procedure and be at least: A. 150 x 109/L B. 250 x 109/L C. 200 x 109/L D. 300 x 109/L

    A. 150 x 109/L

  • 4

    Which of the following precludes acceptance of a plateletpheresis donor? A. Platelet count of 75 × 109 /L in a donor who is a frequent platelet donor B. Plasma loss of 800 mL from plasmapheresis 1 week ago C. Plateletpheresis performed 4 days ago D. Aspirin ingested 7 days ago

    A. Platelet count of 75 × 109 /L in a donor who is a frequent platelet donor

  • 5

    An important determinant of platelet viability during storage is: A. Plasma potassium concentration B. Plasma pH C. Prothrombin time D. Activated partial thromboplastin time

    B. Plasma pH

  • 6

    What is the lowest allowable pH for a platelet component at outdate? A. 6 B. 5.9 C. 6.2 D. 6.8

    C. 6.2

  • 7

    Platelets must be kept in constant motion for which of the following reasons? A. Maintain the pH so the platelets will be alive before transfusion B. Keep the platelets in suspension and prevent clumping of the platelets C. Mimic what is going on in the blood vessels D. Preserve the coagulation factors and platelet viability

    A. Maintain the pH so the platelets will be alive before transfusion

  • 8

    .According to AABB Standards, Platelets prepared from Whole Blood shall have at least A. 5.5 x 1010 platelets per unit in at least 90% of the units tested B. 6.5 x 1010 platelets per unit in 90% of the units tested C. 7.5 x 1010 platelets per unit in 100% of the units tested D. 8.5 x 1010 platelets per unit in 95% of the units tested

    A. 5.5 x 1010 platelets per unit in at least 90% of the units tested

  • 9

    The optimum storage temperature for platelets is: A. - 20ºC B. - 12ºC C. 4ºC D. 22ºC

    D. 22ºC

  • 10

    If a platelet bag is broken or opened, the platelets must be transfused within ____ when stored at 20 to 24 o C A. 4 hours B. 24 hours C. 5 days D. 7 days

    A. 4 hours

  • 11

    What increment of platelets/µL (platelets/L), in the typical 70-kg human, is expected to result from each single unit of random donor platelets (RDP) to recipient? A. 3,000 – 5,000 B. 5,000 – 10,000 C. 20,000 – 25,000 D. 25,000 – 30,000

    B. 5,000 – 10,000

  • 12

    A 70-kg man has a platelet count of 15,000/µL, and there are no complicating factors such as fever or HLA sensitization. If he is given a platelet pool of 6 units, what would you expect his post-transfusion count to be? A. 21,000-27,000/µL B. 25,000-35,000/µL C. 45,000-75,000/µL D. 75,000- 125,000/µL

    C. 45,000-75,000/µL

  • 13

    SHELF-LIFE OF FRESH FROZEN PLASMA stored at -65o C: A. 24 hours B. 5 days C. 1 year D. 7 years

    D. 7 years

  • 14

    According to AABB standards, FRESH FROZEN PLASMA must be infused within what period of time FOLLOWING THAWING? A. 24 hours B. 36 hours C. 48 hours D. 72 hours

    A. 24 hours

  • 15

    FFP can be transfused without regard for: A. ABO type B. Rh type C. Antibody in product D. All of these options

    B. Rh type

  • 16

    A blood component prepared by thawing Fresh Frozen Plasma at refrigerator temperature and removing the fluid portion is: A. Plasma Protein Fraction B. Cryoprecipitate C. Factor IX Complex D. FP24

    B. Cryoprecipitate

  • 17

    Cryoprecipitate contains how many units of Factor VIII? A. 40 B. 80 C. 130 D. 250

    B. 80

  • 18

    Cryoprecipitate may be used to treat all of the following, except: A. von Willebrand’s disease B. Hypofibrinogenemia C. Idiopathic thrombocytopenic purpura (ITP) D. Factor XIII deficiency

    C. Idiopathic thrombocytopenic purpura (ITP)

  • 19

    Although ABO compatibility is preferred, ABO incompatibility is acceptable for which of the following components? A. PF24 B. Cryoprecipitated AHF C. Apheresis Granulocytes D. Apheresis Platelets

    B. Cryoprecipitated AHF

  • 20

    The optimum storage temperature for cryoprecipitate is: A. – 20 ºC B. –12ºC C. 4ºC D. 22ºC

    A. – 20 ºC

  • 21

    Cryoprecipitate maintained in the frozen state of -18 °C or below, has a shelf life of: A. 42 days B. 6 months C. 12 months D. 36 months

    C. 12 months

  • 22

    Cryoprecipitate must be transfused within what period of time FOLLOWING THAWING AND POOLING? A. 4 hours B. 8 hours C. 12 hours D. 24 hours

    A. 4 hours

  • 23

    The primary indication for GRANULOCYTE TRANSFUSION is: A. Prophylactic treatment for infection B. Additional supportive therapy in those patients who are responsive to antibiotic therapy C. Clinical situations where bone marrow recovery is not anticipated D. Severe neutropenia with an infection that is nonpresponsive to antibiotic therapy

    D. Severe neutropenia with an infection that is nonpresponsive to antibiotic therapy

  • 24

    Irradiation of a unit of Red Blood Cells is done to prevent the replication of donor: A. Granulocytes B. Lymphocytes C. Red cells D. Platelets

    B. Lymphocytes

  • 25

    The purpose of a low-dose IRRADIATION of blood components is to: A. Prevent posttransfusion purpura B. Sterilize components C. Prevent graft-vs-host (GVH) disease D. Prevent noncardiogenic pulmonary edema

    C. Prevent graft-vs-host (GVH) disease

  • 26

    A cancer patient recently developed a severe infection. The patient’s hemoglobin is 8 g/dL owing to chemotherapy with a drug known to cause bone marrow depression and immunodeficiency. Which blood products are indicated for this patient? A. Liquid plasma and cryoprecipitate B. Crossmatched platelets and washed RBCs C. Factor IX concentrates and FFP D. Irradiated RBCs, platelets, and granulocytes

    D. Irradiated RBCs, platelets, and granulocytes

  • 27

    All Blood Collection Units (BCUs) shall achieve and maintain ___ voluntary blood donation. The key function of the BCU is effective donor recruitment and safe blood collection. A. 10% B. 50% C. 70% D. 100%

    D. 100%

  • 28

    Whole blood collected in BCUs shall be stored immediately after collection and validation in a blood bank refrigerator or COLD BOX at 1 to 6 oC. As much as possible, blood should be submitted to the Blood Bank/Center within ____ after collection. A. 6 hours B. 8 hours C. 12 hours D. 24 hours

    D. 24 hours

  • 29

    The blood warmer should have automatic temperature control with an alarm that will sound if the blood is warmed over ___°C. A. 30 oC B. 37 oC C. 40 oC D. 42 oC

    D. 42 oC

  • 30

    LEUKOCYTE-POOR RED BLOOD CELLS would most likely be indicated for patients with a history of: A. Febrile transfusion reaction B. Hemophilia A C. Iron deficiency anemia D. von Willebrand disease

    A. Febrile transfusion reaction

  • 31

    The type of cell MOST FREQUENTLY RESPONSIBLE FOR FEBRILE TRANSFUSION REACTIONS is the: A. Erythrocyte B. Lymphocyte C. Granulocyte D. Platelets

    C. Granulocyte

  • 32

    With or without documentation of the existence of specific antibodies, the AABB recommends leukocytepoor preparations only after a patient has had at least ___ febrile nonhemolytic transfusion reactions. A. One B. Two C. Three D. Four

    B. Two

  • 33

    A transfusion reaction that usually appears rapidly during transfusion termed “WARM” and may result in fever, shock, or death is which one of the following listed reactions? A. Hemolytic B. Bacterial contamination C. TACO D. Allergic

    B. Bacterial contamination

  • 34

    An emergency trauma patient requires transfusion. Six units of blood are ordered stat. There is no time to draw a patient sample. O-negative blood is released. When will compatibility testing be performed? A. Compatibility testing must be performed before blood is issued B. Compatibility testing will be performed when a patient sample is available C. Compatibility testing may be performed immediately using donor serum D. Compatibility testing is not necessary when blood is released in emergency situations

    B. Compatibility testing will be performed when a patient sample is available

  • 35

    PHOTOTHERAPY is most useful for which of the following antibodies: A. Anti-A B. Anti-D C. Anti-K D. Anti-S

    A. Anti-A

  • 36

    Advantages of CORDOCENTESIS: 1. Allows measurement of fetal hemoglobin and hematocrit levels 2. Allows antigen typing of fetal blood 3. Allows direct transfusion of fetal circulation 4. Decreases risk of trauma to the placenta A. 1 and 3 B. 2 and 4 C. 1, 2 and 3 D. 1, 2, 3 and 4

    C. 1, 2 and 3

  • 37

    The LILEY METHOD of predicting the severity of hemolytic disease of the newborn is based on the amniotic fluid: A. Bilirubin concentration by standard method B. Rh determination C. Change in optical density measured to 450 nm D. Ratio of lecithin to sphingomyelin

    C. Change in optical density measured to 450 nm

  • 38

    Which of the following is the preferred specimen for the initial compatibility testing in exchange transfusion therapy? A. Maternal serum B. Paternal serum C. Eluate prepared from infant’s red blood cells D. Infant’s post-exchange serum

    A. Maternal serum

  • 39

    EXCHANGE TRANSFUSIONS are used primarily to: A. Provide antigen negative RBCs B. Remove antibody C. Remove antibody coated RBCs D. Remove high levels of unconjugated bilirubin and thus prevent kernicterus

    D. Remove high levels of unconjugated bilirubin and thus prevent kernicterus

  • 40

    All of the following are routinely performed on a cord blood sample except: A. Forward ABO typing B. Antibody screen C. Rh typing D. DAT

    B. Antibody screen

  • 41

    All of the following are reasons for a positive DAT on cord blood cells of a newborn except: A. High concentrations of Wharton’s jelly on cord cells B. Immune anti-A from an O mother on the cells of an A baby C. Immune anti-D from an Rh negative mother on the cells of an Rh-positive baby D. Immune anti-K from an K-negative mother on the cells of a K-negative baby

    D. Immune anti-K from an K-negative mother on the cells of a K-negative baby

  • 42

    Infants do not require crossmatching during: A. The first 4 months B. The first 6 months C. The first year D. An indefinite period if a parent’s blood is used

    A. The first 4 months

  • 43

    Preliminary blood bank testing for neonates <4 months of age must include: A. ABO forward typing and ABO reverse typing B. ABO reverse typing and testing for K antigen C. ABO reverse typing and antibody detection testing D. ABO forward typing and Rh testing for D antigen

    D. ABO forward typing and Rh testing for D antigen

  • 44

    Recommended speed of the SEROFUGE for agglutination grading: A. 500 g B. 800 g C. 1,000 g D. 2,000 g

    C. 1,000 g

  • 45

    Heavy spin centrifugation: A. 2, 000 x g for 2 to 3 minutes B. 5, 000 x g for 5 minutes C. 10,000 x g for 5 minutes D. 15,000 x g for 10 minutes

    B. 5, 000 x g for 5 minutes

  • 46

    All blood banks as mandated by law must have a: A. Water fountain B. Written laboratory safety program C. BSC D. Foot-operated hand wash

    B. Written laboratory safety program

  • 47

    One of the best ways to protect employees and keep a safe laboratory environment is to provide employees with: A. Health insurance B. Safety education C. Rest breaks D. Fluid-repellent laboratory coats

    B. Safety education

  • 48

    What is the purpose of competency assessment? A. Identify employees in need of retraining B. Evaluate an individual’s level of knowledge during a job interview C. Identify employees who need to be fired D. All of the above

    A. Identify employees in need of retraining

  • 49

    A56-year-old female with cold agglutinin disease has a positive direct antiglobulin test (DAT). When the DAT is repeated using monospecific antiglobulin sera, which of the following is most likely to be detected? A. lgM B. lgG C. C3d D. C4a

    C. C3d

  • 50

    A crossmatch is positive at AHG phase with polyspecific AHG reagent but is negative with monospecific anti-IgG AHG reagent. This may indicate the antibody: A. Is a weak anti-D B. Is a clinically insignificant Lewis antibody C. Can cause decreased survival of transfused RBCs D. Is a Duffy antibody

    B. Is a clinically insignificant Lewis antibody

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    The percentage of red cells recovered after thawing and deglycerolization of frozen blood is: A. 35% B. 50% C. 70% D. 80%

    D. 80%

  • 2

    Frozen and thawed RBCs processed in an open system can be stored for how many days/hours? A. 3 days B. 6 hours C. 24 hours D. 15 days

    C. 24 hours

  • 3

    For apheresis donors who donate platelets, a platelet count must be performed prior to the procedure and be at least: A. 150 x 109/L B. 250 x 109/L C. 200 x 109/L D. 300 x 109/L

    A. 150 x 109/L

  • 4

    Which of the following precludes acceptance of a plateletpheresis donor? A. Platelet count of 75 × 109 /L in a donor who is a frequent platelet donor B. Plasma loss of 800 mL from plasmapheresis 1 week ago C. Plateletpheresis performed 4 days ago D. Aspirin ingested 7 days ago

    A. Platelet count of 75 × 109 /L in a donor who is a frequent platelet donor

  • 5

    An important determinant of platelet viability during storage is: A. Plasma potassium concentration B. Plasma pH C. Prothrombin time D. Activated partial thromboplastin time

    B. Plasma pH

  • 6

    What is the lowest allowable pH for a platelet component at outdate? A. 6 B. 5.9 C. 6.2 D. 6.8

    C. 6.2

  • 7

    Platelets must be kept in constant motion for which of the following reasons? A. Maintain the pH so the platelets will be alive before transfusion B. Keep the platelets in suspension and prevent clumping of the platelets C. Mimic what is going on in the blood vessels D. Preserve the coagulation factors and platelet viability

    A. Maintain the pH so the platelets will be alive before transfusion

  • 8

    .According to AABB Standards, Platelets prepared from Whole Blood shall have at least A. 5.5 x 1010 platelets per unit in at least 90% of the units tested B. 6.5 x 1010 platelets per unit in 90% of the units tested C. 7.5 x 1010 platelets per unit in 100% of the units tested D. 8.5 x 1010 platelets per unit in 95% of the units tested

    A. 5.5 x 1010 platelets per unit in at least 90% of the units tested

  • 9

    The optimum storage temperature for platelets is: A. - 20ºC B. - 12ºC C. 4ºC D. 22ºC

    D. 22ºC

  • 10

    If a platelet bag is broken or opened, the platelets must be transfused within ____ when stored at 20 to 24 o C A. 4 hours B. 24 hours C. 5 days D. 7 days

    A. 4 hours

  • 11

    What increment of platelets/µL (platelets/L), in the typical 70-kg human, is expected to result from each single unit of random donor platelets (RDP) to recipient? A. 3,000 – 5,000 B. 5,000 – 10,000 C. 20,000 – 25,000 D. 25,000 – 30,000

    B. 5,000 – 10,000

  • 12

    A 70-kg man has a platelet count of 15,000/µL, and there are no complicating factors such as fever or HLA sensitization. If he is given a platelet pool of 6 units, what would you expect his post-transfusion count to be? A. 21,000-27,000/µL B. 25,000-35,000/µL C. 45,000-75,000/µL D. 75,000- 125,000/µL

    C. 45,000-75,000/µL

  • 13

    SHELF-LIFE OF FRESH FROZEN PLASMA stored at -65o C: A. 24 hours B. 5 days C. 1 year D. 7 years

    D. 7 years

  • 14

    According to AABB standards, FRESH FROZEN PLASMA must be infused within what period of time FOLLOWING THAWING? A. 24 hours B. 36 hours C. 48 hours D. 72 hours

    A. 24 hours

  • 15

    FFP can be transfused without regard for: A. ABO type B. Rh type C. Antibody in product D. All of these options

    B. Rh type

  • 16

    A blood component prepared by thawing Fresh Frozen Plasma at refrigerator temperature and removing the fluid portion is: A. Plasma Protein Fraction B. Cryoprecipitate C. Factor IX Complex D. FP24

    B. Cryoprecipitate

  • 17

    Cryoprecipitate contains how many units of Factor VIII? A. 40 B. 80 C. 130 D. 250

    B. 80

  • 18

    Cryoprecipitate may be used to treat all of the following, except: A. von Willebrand’s disease B. Hypofibrinogenemia C. Idiopathic thrombocytopenic purpura (ITP) D. Factor XIII deficiency

    C. Idiopathic thrombocytopenic purpura (ITP)

  • 19

    Although ABO compatibility is preferred, ABO incompatibility is acceptable for which of the following components? A. PF24 B. Cryoprecipitated AHF C. Apheresis Granulocytes D. Apheresis Platelets

    B. Cryoprecipitated AHF

  • 20

    The optimum storage temperature for cryoprecipitate is: A. – 20 ºC B. –12ºC C. 4ºC D. 22ºC

    A. – 20 ºC

  • 21

    Cryoprecipitate maintained in the frozen state of -18 °C or below, has a shelf life of: A. 42 days B. 6 months C. 12 months D. 36 months

    C. 12 months

  • 22

    Cryoprecipitate must be transfused within what period of time FOLLOWING THAWING AND POOLING? A. 4 hours B. 8 hours C. 12 hours D. 24 hours

    A. 4 hours

  • 23

    The primary indication for GRANULOCYTE TRANSFUSION is: A. Prophylactic treatment for infection B. Additional supportive therapy in those patients who are responsive to antibiotic therapy C. Clinical situations where bone marrow recovery is not anticipated D. Severe neutropenia with an infection that is nonpresponsive to antibiotic therapy

    D. Severe neutropenia with an infection that is nonpresponsive to antibiotic therapy

  • 24

    Irradiation of a unit of Red Blood Cells is done to prevent the replication of donor: A. Granulocytes B. Lymphocytes C. Red cells D. Platelets

    B. Lymphocytes

  • 25

    The purpose of a low-dose IRRADIATION of blood components is to: A. Prevent posttransfusion purpura B. Sterilize components C. Prevent graft-vs-host (GVH) disease D. Prevent noncardiogenic pulmonary edema

    C. Prevent graft-vs-host (GVH) disease

  • 26

    A cancer patient recently developed a severe infection. The patient’s hemoglobin is 8 g/dL owing to chemotherapy with a drug known to cause bone marrow depression and immunodeficiency. Which blood products are indicated for this patient? A. Liquid plasma and cryoprecipitate B. Crossmatched platelets and washed RBCs C. Factor IX concentrates and FFP D. Irradiated RBCs, platelets, and granulocytes

    D. Irradiated RBCs, platelets, and granulocytes

  • 27

    All Blood Collection Units (BCUs) shall achieve and maintain ___ voluntary blood donation. The key function of the BCU is effective donor recruitment and safe blood collection. A. 10% B. 50% C. 70% D. 100%

    D. 100%

  • 28

    Whole blood collected in BCUs shall be stored immediately after collection and validation in a blood bank refrigerator or COLD BOX at 1 to 6 oC. As much as possible, blood should be submitted to the Blood Bank/Center within ____ after collection. A. 6 hours B. 8 hours C. 12 hours D. 24 hours

    D. 24 hours

  • 29

    The blood warmer should have automatic temperature control with an alarm that will sound if the blood is warmed over ___°C. A. 30 oC B. 37 oC C. 40 oC D. 42 oC

    D. 42 oC

  • 30

    LEUKOCYTE-POOR RED BLOOD CELLS would most likely be indicated for patients with a history of: A. Febrile transfusion reaction B. Hemophilia A C. Iron deficiency anemia D. von Willebrand disease

    A. Febrile transfusion reaction

  • 31

    The type of cell MOST FREQUENTLY RESPONSIBLE FOR FEBRILE TRANSFUSION REACTIONS is the: A. Erythrocyte B. Lymphocyte C. Granulocyte D. Platelets

    C. Granulocyte

  • 32

    With or without documentation of the existence of specific antibodies, the AABB recommends leukocytepoor preparations only after a patient has had at least ___ febrile nonhemolytic transfusion reactions. A. One B. Two C. Three D. Four

    B. Two

  • 33

    A transfusion reaction that usually appears rapidly during transfusion termed “WARM” and may result in fever, shock, or death is which one of the following listed reactions? A. Hemolytic B. Bacterial contamination C. TACO D. Allergic

    B. Bacterial contamination

  • 34

    An emergency trauma patient requires transfusion. Six units of blood are ordered stat. There is no time to draw a patient sample. O-negative blood is released. When will compatibility testing be performed? A. Compatibility testing must be performed before blood is issued B. Compatibility testing will be performed when a patient sample is available C. Compatibility testing may be performed immediately using donor serum D. Compatibility testing is not necessary when blood is released in emergency situations

    B. Compatibility testing will be performed when a patient sample is available

  • 35

    PHOTOTHERAPY is most useful for which of the following antibodies: A. Anti-A B. Anti-D C. Anti-K D. Anti-S

    A. Anti-A

  • 36

    Advantages of CORDOCENTESIS: 1. Allows measurement of fetal hemoglobin and hematocrit levels 2. Allows antigen typing of fetal blood 3. Allows direct transfusion of fetal circulation 4. Decreases risk of trauma to the placenta A. 1 and 3 B. 2 and 4 C. 1, 2 and 3 D. 1, 2, 3 and 4

    C. 1, 2 and 3

  • 37

    The LILEY METHOD of predicting the severity of hemolytic disease of the newborn is based on the amniotic fluid: A. Bilirubin concentration by standard method B. Rh determination C. Change in optical density measured to 450 nm D. Ratio of lecithin to sphingomyelin

    C. Change in optical density measured to 450 nm

  • 38

    Which of the following is the preferred specimen for the initial compatibility testing in exchange transfusion therapy? A. Maternal serum B. Paternal serum C. Eluate prepared from infant’s red blood cells D. Infant’s post-exchange serum

    A. Maternal serum

  • 39

    EXCHANGE TRANSFUSIONS are used primarily to: A. Provide antigen negative RBCs B. Remove antibody C. Remove antibody coated RBCs D. Remove high levels of unconjugated bilirubin and thus prevent kernicterus

    D. Remove high levels of unconjugated bilirubin and thus prevent kernicterus

  • 40

    All of the following are routinely performed on a cord blood sample except: A. Forward ABO typing B. Antibody screen C. Rh typing D. DAT

    B. Antibody screen

  • 41

    All of the following are reasons for a positive DAT on cord blood cells of a newborn except: A. High concentrations of Wharton’s jelly on cord cells B. Immune anti-A from an O mother on the cells of an A baby C. Immune anti-D from an Rh negative mother on the cells of an Rh-positive baby D. Immune anti-K from an K-negative mother on the cells of a K-negative baby

    D. Immune anti-K from an K-negative mother on the cells of a K-negative baby

  • 42

    Infants do not require crossmatching during: A. The first 4 months B. The first 6 months C. The first year D. An indefinite period if a parent’s blood is used

    A. The first 4 months

  • 43

    Preliminary blood bank testing for neonates <4 months of age must include: A. ABO forward typing and ABO reverse typing B. ABO reverse typing and testing for K antigen C. ABO reverse typing and antibody detection testing D. ABO forward typing and Rh testing for D antigen

    D. ABO forward typing and Rh testing for D antigen

  • 44

    Recommended speed of the SEROFUGE for agglutination grading: A. 500 g B. 800 g C. 1,000 g D. 2,000 g

    C. 1,000 g

  • 45

    Heavy spin centrifugation: A. 2, 000 x g for 2 to 3 minutes B. 5, 000 x g for 5 minutes C. 10,000 x g for 5 minutes D. 15,000 x g for 10 minutes

    B. 5, 000 x g for 5 minutes

  • 46

    All blood banks as mandated by law must have a: A. Water fountain B. Written laboratory safety program C. BSC D. Foot-operated hand wash

    B. Written laboratory safety program

  • 47

    One of the best ways to protect employees and keep a safe laboratory environment is to provide employees with: A. Health insurance B. Safety education C. Rest breaks D. Fluid-repellent laboratory coats

    B. Safety education

  • 48

    What is the purpose of competency assessment? A. Identify employees in need of retraining B. Evaluate an individual’s level of knowledge during a job interview C. Identify employees who need to be fired D. All of the above

    A. Identify employees in need of retraining

  • 49

    A56-year-old female with cold agglutinin disease has a positive direct antiglobulin test (DAT). When the DAT is repeated using monospecific antiglobulin sera, which of the following is most likely to be detected? A. lgM B. lgG C. C3d D. C4a

    C. C3d

  • 50

    A crossmatch is positive at AHG phase with polyspecific AHG reagent but is negative with monospecific anti-IgG AHG reagent. This may indicate the antibody: A. Is a weak anti-D B. Is a clinically insignificant Lewis antibody C. Can cause decreased survival of transfused RBCs D. Is a Duffy antibody

    B. Is a clinically insignificant Lewis antibody